CLDN18 and neoplasm: It should be noted that ZL-1211 is capable to mount ADCC activity for KATOIII expressing minimal amount of CLDN18.2 even with low effector:tumor (E:T) ratio (1:1) while benchmark did not show efficacy at the E:T ratio, suggesting that ZL-1211 may be able to be used for treatment of CLDN18.2-low as well as NK-low gastric tumors.